Sunday, 24 January 2010

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Oral cladribine reduced relapse rates and lowered the risk of sustained disability in patients with relapsing–remitting multiple sclerosis. Patients who were treated with cladribine had large reductions in lymphocyte counts and more infections, including one death from reactivation of tuberculosis.

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.